All In Biotech

BLA 125388 · Seattle Genetics

Adcetris

Brentuximab Vedotin · Injection · CD30-directed Immunoconjugate

NovelBreakthrough therapyAccelerated approvalPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Feb 11, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2011

Aug 19, 2011

Approved uses

9

Original approval plus efficacy supplements

Registered trials

189

19 Phase 3, 23 recruiting

FAERS reports

10,402

9,478 serious, 1,994 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) JC virus infection resulting in PML and death can occur in patients receiving ADCETRIS [see Warnings and Precautions (5.9) , Adverse Reactions (6.1) ] . WARNING: PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) See full prescribing information for complete boxed warning. JC virus infection resulting in PML and death can occur in patients receiving ADCETRIS ( 5.9 , 6.1 ).

What it is approved for

From the label in effect Nov 11, 2025.

ADCETRIS is a CD30-directed antibody and microtubule inhibitor conjugate indicated for treatment of: • Adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vinblastine, and dacarbazine ( 1.1 ). • Pediatric patients 2 years and older with previously untreated high risk classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide ( 1.2 ). • Adult patients with classical Hodgkin lymphoma (cHL) at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation ( 1.3 ). • Adult patients with classical Hodgkin lymphoma (cHL) after failure of auto-HSCT or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates ( 1.4 ). • Adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified (NOS), in combination with cyclophosphamide, doxorubicin, and prednisone ( 1.5 ). • Adult patients with systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen ( 1.6 ). • Adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy ( 1.7 ). • Adult patients with relapsed or refractory large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) NOS, DLBCL arising from indolent lymphoma, or high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy who are not eligible for auto-HSCT or CAR T-cell...

Mechanism: CD30 is a member of the tumor necrosis factor receptor family and is expressed on the surface of sALCL cells and on Hodgkin Reed-Sternberg (HRS) cells in cHL. CD30 is variably expressed in other T-cell lymphomas. Expression of CD30 on healthy tissue and cells is limited. In vitro data suggest that signaling through CD30-CD30L binding may affect cell survival and proliferation. Brentuximab vedotin is an antibody-drug conjugate (ADC). The antibody is a chimeric IgG1 directed against CD30. The small molecule, MMAE, is a microtubule-disrupting agent. MMAE is covalently attached to the antibody...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Feb 11, 2025 Supplement 108 · Efficacy OrphanLabelLetterReview
  • Jun 14, 2023 Supplement 107 · Efficacy OrphanLetterLabel
  • Nov 10, 2022 Supplement 106 · Efficacy · priority review LabelLetter
  • Nov 16, 2018 Supplement 99 · Efficacy · priority review Breakthrough therapyOrphanLabelLetter
  • Mar 20, 2018 Supplement 97 · Efficacy · priority review Breakthrough therapyOrphanLabelLetter
  • Nov 9, 2017 Supplement 94 · Efficacy · priority review Breakthrough therapyOrphanLabelLetter
  • Aug 17, 2015 Supplement 80 · Efficacy · priority review OrphanLabelLetter
  • Aug 19, 2011 Supplement 6 · Efficacy · priority review Accelerated approvalOrphan
  • Aug 19, 2011 Original approval · Type 1 - New Molecular Entity · priority review NovelAccelerated approvalOrphanLabelReviewOther Important Information from FDA
1 products under this application
  • ADCETRIS · BRENTUXIMAB VEDOTIN 50MG/VIAL · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Brentuximab Vedotin" as an intervention, any sponsor and status, largest first.

All 189 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use1,358
  • febrile neutropenia776
  • neuropathy peripheral725
  • pyrexia694
  • neutropenia599
  • death594
  • hodgkin^s disease462
  • nausea407
  • anaemia399
  • thrombocytopenia388
  • diarrhoea387
  • drug ineffective378

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
201116
2012151
2013182
2014294
2015377
2016453
2017609
2018677
2019887
2020940
2021927
2022821
2023855
20241,517
20251,040
2026656

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Adcetris (Brentuximab Vedotin)

2024 spending

$3.5M

Beneficiaries

25

106 claims

Per beneficiary

$140,843

$11,107.46 per unit

View as table
YearSpending
2020$1,207,676
2021$2,395,839
2022$3,044,765
2023$3,056,726
2024$3,521,063

Part B: Adcetris (Brentuximab Vedotin) · HCPCS J9042

2024 spending

$187M

Beneficiaries

1,363

6,255 claims

Per beneficiary

$137,180

2024 ASP limit $235.20 per unit

View as table
YearSpending
2020$161,368,351
2021$164,383,360
2022$186,209,799
2023$193,419,173
2024$186,976,535

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 226 on PubMed

Sponsor: Seattle Genetics

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.